News

Under the deal, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for tafoxiparin in the US, European, CIS and

ABP 501 is being developed by the company as a biosimilar to adalimumab, an anti-TNF-a monoclonal antibody. The trial evaluated the efficacy and safety of ABP 501 compared

The collaboration builds on two independent research programmes at both the ICR and EMD Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.

The trial is being conducted in Germany for a rare form of bile duct cancer for which currently there is no acceptable therapy. About 200 patients will be

In this cohort, three patients were evaluated and they showed that Liposomal Grb-2 is safe and well tolerated with the drug showing signs of anti-leukemia activity. The Phase

NurOwn includes autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors. The company is currently, evaluating NurOwn in a randomized, double-blind, placebo-controlled Phase II clinical

Treatment for glioma, which is the most common form of primary brain cancer, remains a significant unmet medical need. The FDA Orphan Drug Designation provides companies with development

As patients find that they are unable to refill their hydrocodone prescription, this paper presents alternatives that should be discussed with their physician. The release of the white

Concomitant with this news, DBM, Inc. was also approved to proceed with the Phase 2 portion of a Fast Track SBIR-funded program funded by the NIH to develop